Purchase this article with an account.
A. Perez Montesinos, M. E. Torres-Soriano, V. Kon-Jara, J. Diaz-Rubio, M. Hernandez-Rojas, V. Cubas-Lorenzo, O. Martinez-Guzman, J. Fromow-Guerra, H. Quiroz-Mercado, J. M. Jimenez-Sierra; Electrophysiologic Changes With Intravitreal Bevacizumab in Patients With Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2894.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the findings in the electroretinographic response in diabetic patients with proliferative diabetic retinopathy after treatment with intravitreal bevacizumab, using standard electroretinogram (st ERG).
Twelve patients with proliferative diabetic retinopathy without previous pan-retinal photocoagulation, were treated with intravitreal bevacizumab (2.5mg/0.1cc). Evaluation with st ERG was performed at baseline and ten days after treatment. Best corrected visual acuity and fluorescein angiography were also evaluated.
All subjects tested had response improvement or stabilization of the st-ERG after treatment. Improvement in rod response after intravitreal bevacizumab resulted statistically significant (p < 0.05).
Our data suggest that the use of intravitreal bevacizumab results in improvement of scotopic st ERG responses, increasing the amplitude and decreasing the implicit time. This improvement could be correlated with an improvement in retinal perfusion and with a lack of retinal toxicity.
This PDF is available to Subscribers Only